Research

=

Cancer immunotherapies, first and foremost checkpoint blockade therapy (anti-CTLA4 and anti-PD-1/PD-L1), have revolutionized cancer treatment. Despite these advances only a fraction of cancer patients responds to immunotherapeutic interventions. Even for cancer types that typically show high response rates, only a fraction of patients respond. We aim to understand which tumor cell-intrinsic, tissue-macroenvironmental and environmental factors mediate resistance mechanisms against immunotherapy by affecting T cell infiltration into tumors.

Dendritic cells within a productive anti-tumor immune response

Dendritic cells within a productive anti-tumor immune response

Dendritic cells are a diverse group of professional antigen-presenting cells responsible for sensing danger signals, including cancer cells, throughout our body. more >>

Anti-tumor immune responses in lung cancer

Anti-tumor immune responses in lung cancer

Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths in the US, despite the fact that some patients benefit from checkpoint blockade therapy. more >>

Anti-tumor immune responses in pancreatic cancer

Anti-tumor immune responses in pancreatic cancer

Pancreatic ductal cell adenocarcinoma is one of the most aggressive cancer types, and thus far immunotherapeutic interventions have failed to provide survival benefits. more >>

Local and systemic factors impacting the tumor-immune microenvironment

Local and systemic factors impacting the tumor-immune microenvironment

Anti-tumor immune responses can be influenced by a variety of factors ranging from the origin of the cancer cell type, the tissue the tumor arises from, but also from the activation status of the immune system. more >>